The targeting specificity of TU17:MTD to tumor cells is likely to be determined by the “RPARPAR” sequence that is previously known to bind to NRP-1, a co-receptor for vascular endothelial growth factor (VEGF), expressed in tumor vessels and in most carcinomas [24–26]. Here, VEGFA is linked to neoplasm.